Iovance Biotherapeutics (IOVA) Cost of Revenue (2023 - 2026)

Iovance Biotherapeutics (IOVA) has reported Cost of Revenue for 4 consecutive years, with $42.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cost of Revenue fell 0.51% year-over-year to $42.5 million; the TTM figure through Mar 2026 stood at $180.8 million (up 26.05% YoY), while the FY2025 annual figure was $173.2 million, up 85.72% from the prior year.
• Cost of Revenue retreated to $42.5 million in Q1 2026 per IOVA's latest filing, from $43.1 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $56.7 million in Q2 2025 and bottomed at -$5.4 million in Q4 2023.
• Historically, Cost of Revenue has averaged $27.7 million across 4 years, with a median of $34.7 million in 2024.
• Annual changes were most pronounced in 2024 — Cost of Revenue soared 1430.15% — and 2026, when it slipped 0.51%.
• Iovance Biotherapeutics' Cost of Revenue stood at -$5.4 million in 2023, then jumped by 805.41% to $37.8 million in 2024, then advanced by 14.08% to $43.1 million in 2025, then fell by 1.42% to $42.5 million in 2026.
• Business Quant data shows IOVA's Cost of Revenue at $42.5 million in Q1 2026, $43.1 million in Q4 2025, and $38.5 million in Q3 2025.